EGFR and lung cancer: Specifically, cell line panels compiled for individual cancer types have helped identify markers predictive of lineage-specific drug responses, such as associating P27(KIP1) with Trastuzumab resistance in breast cancers and linking epithelial-mesenchymal transition genes to resistance to EGFR inhibitors in lung cancers [9]–[11].